Please Wait...

BioClinica Announces Completion of the First Thorough QT Study in China and a Strategic Partnership with Teda International Cardiovascular Hospital (TICH)

– Global Company Expands Operational Capabilities to Support Growing Clinical Trials in Asia Pacific –

June 17, 2013

BioClinica®, Inc., a global provider of clinical trial management services, has recently announced several major initiatives to better serve its growing sponsor client base in China and other Asia Pacific countries, following its March 2013 merger with CoreLab Partners, a leading provider of cardiac safety monitoring and imaging core lab services. The achievements include the completion of the first regulatory-mandated Thorough QT (TQT) cardiac safety study in China, a strategic partnership with TEDA International Cardiovascular Hospital (TICH) in Tianjin, China, and the expansion of local operational support for cardiac safety monitoring and imaging core lab services in Asia.

First TQT Study in China
This landmark cardiac safety study, requested by the China Food and Drug Administration (CFDA), was conducted in collaboration with the TEDA International Cardiovascular Hospital (TICH) in support of a new drug approval for a domestic sponsor. BioClinica provided both in-country operational and scientific support for the study, including study design, project management, ECG data collection and extraction, ECG analysis and assistance with regulatory submission. This TQT study builds on BioClinica's cardiac safety leadership in the region, having successfully completed the first regulatory-mandated TQT study in Japan in 2010.

"Cardiac safety is gaining momentum in China and I am pleased to have been part of this collaborative TQT study in support of the changing regulatory landscape surrounding cardiac safety" said Boaz Mendzelevski, MD, BioClinica's Vice President of Cardiology. "The evolving regulatory environment in China will necessitate new safety standards and assessments of a similar nature for drugs in the pipeline, resulting in increased collaborative efforts and consultative input in support of Chinese pharmaceutical companies seeking domestic and global marketing approval for their new drugs". Details of this unique TQT study were presented at the recent annual DIA China meeting in Beijing by Dr. Jennifer (Jie) Hou, head of the TICH Phase 1 Clinical Trial Unit, and Dr. Mendzelevski.

"This study not only represents a remarkable success for BioClinica, but signals our continued investment of resources and expanding operational support in the emerging Asia Pacific markets" added Mark Weinstein, President and CEO of BioClinica. On the heels of this study, BioClinica will be supporting additional TQT studies in China later this year.

Partnership with TICH
Following the success of the first TQT study in China, BioClinica has announced a strategic partnership with the TEDA International Cardiovascular Hospital. Under this partnership, BioClinica will provide integrated clinical and centralized cardiac safety services at TICH for domestic and foreign sponsors seeking drug approvals in China. "There is a substantial need for cardiac safety services in certified clinical facilities, and this partnership will make it easier for Pharmaceutical sponsors to meet changing regulatory standards in the region" said Dr. Onglee (Li) Weng, Director of Operations in Asia, BioClinica. "We are thrilled to be able to support new regulatory initiatives in China and are poised to make a large impact on the development of safer pharmaceuticals in the Asia Pacific Region" added President and CEO Mark Weinstein.

Expanded Service, Scope and Clinical Trial Support in Asia Pacific Region
As part of BioClinica's commitment to supporting clinical drug development in Asia Pacific, BioClinica has developed strategic partnerships with local medical technology providers, made key infrastructure investments, and established local scientific and medical expertise so as to provide a comprehensive suite of cardiac safety solutions and imaging core lab services for clinical trial sponsors. Under the leadership of Dr. Onglee (Li) Weng, Director of Operations in Asia, BioClinica has added significant personnel to its workforce in China and Japan to fulfill key roles including DICOM conversion, medical image quality assurance, medical image management support, project management, and business development. By providing in-country support for clinical trials in Japan and China, BioClinica is able to offer high-quality services, local regulatory expertise and fast turnaround times for Asian-based clinical trials.

BioClinica representatives will be available to discuss Cardiac Safety Solutions at the Drug Information Association annual meeting June 24th through 26th in Boston, Massachusetts in Booth 1210. Jeffrey Heilbraun, MS, BioClinica's Director of Strategic Development, will present on the topic "Off-target Blood Pressure Changes and Evaluation in Drug Development: Safety, Clinical and Regulatory Considerations" on June 27th at 10:45AM as part of the Clinical Safety and Pharmacovigilance track.

Chinese Press Release  |  Japanese Press Release

About TEDA International CV Hospital (TICH)
TEDA International Cardiovascular Hospital is a public, non-profit, three A-level hospital with granted Joint Commission International Accreditation. TICH has met international standards in terms of patient safety and service quality. The hospital has a state of the art phase I clinical trial center and a well-equipped central laboratory. TICH has clinical trial certification from the Chinese Food & Drug administration and a ISO15189 laboratory accreditation certificate by the China National Accreditation Service for conformity assessment. There have been national and international clinical trials at TICH.

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's cloud-based offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers a global network of research sites and patient recruitment services to provide committed, detail-focused service through all stages of drug development. The company's thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.

Learn more about Bioclinica and our Clinical Adjudication and other offerings at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

ICYMI: Take a look at Bioclinica Clinical Adjudication that caught the judges' eye in the recent Scrip Awards. It's… https://t.co/gPk4aLmTuA
Bioclinica (2 weeks ago)
Still time to catch up with Aina Lihn, Kathleen Kane, Anette Vierning and other Bioclinica folks at #PCTRIALS https://t.co/E3qxdjqTV5
Bioclinica (3 weeks ago)
Awesome day 2 at #PCTRIALS in Barcelona! Great to connect w new & long-time partners & #lifescience clients! https://t.co/ElM3VPCoSk
Bioclinica (3 weeks ago)
Great talk by @bioclinica's CIO & EVP Technology Gavin Nichol at #PCTRIALS 2018 on #FDA recent guidance on EHR EDC… https://t.co/geIjGIFL06
Bioclinica (3 weeks ago)
Great talk by @bioclinica's CIO & EVP Technology Gavin Nichols at #PCTRIALS 2018 on #FDA recent guidance on EHR EDC… https://t.co/agqP32q09W
Bioclinica (3 weeks ago)
Ask us about technology-enabled clinical development powered by science! Hear our CIO in a day 2 talk. See… https://t.co/iZyF8ixV79
Bioclinica (3 weeks ago)

Latest Blogs:

Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner